These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21670663)

  • 1. Activation of coagulation by a thalidomide-based regimen.
    Hoshi A; Matsumoto A; Chung J; Isozumi Y; Koyama T
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):532-40. PubMed ID: 21670663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro.
    Gao Y; Ma G; Liu S; Teng Y; Wang Y; Su Y
    Thromb Res; 2015 Jun; 135(6):1154-9. PubMed ID: 25840743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
    Isozumi Y; Arai R; Fujimoto K; Koyama T
    PLoS One; 2013; 8(5):e64369. PubMed ID: 23696885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release.
    Fu Y; Zhou J; Li H; Cao F; Su Y; Fan S; Li Y; Wang S; Li L; Gilbert GE; Shi J
    Thromb Haemost; 2010 Dec; 104(6):1235-41. PubMed ID: 20886178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes.
    Swystun LL; Shin LY; Beaudin S; Liaw PC
    J Thromb Haemost; 2009 Apr; 7(4):619-26. PubMed ID: 19187077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis.
    Shannon EJ; Sandoval F
    Int Immunopharmacol; 2010 Apr; 10(4):487-92. PubMed ID: 20123041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis.
    Henriksson CE; Klingenberg O; Ovstebø R; Joø GB; Westvik AB; Kierulf P
    Thromb Haemost; 2005 Dec; 94(6):1236-44. PubMed ID: 16411400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity.
    Boles JC; Williams JC; Hollingsworth RM; Wang JG; Glover SL; Owens AP; Barcel DA; Kasthuri RS; Key NS; Mackman N
    Thromb Res; 2012 Feb; 129(2):197-203. PubMed ID: 21762960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity.
    Lechner D; Kollars M; Gleiss A; Kyrle PA; Weltermann A
    J Thromb Haemost; 2007 Dec; 5(12):2445-52. PubMed ID: 17922809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses.
    Morel O; Morel N; Freyssinet JM; Toti F
    Platelets; 2008 Feb; 19(1):9-23. PubMed ID: 18231934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266].
    Lin RF; Lu H; Liu P; Wang YR; Shen WY; Wu YJ; Zhang JF; Fei XM; Ge Z; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1200-3. PubMed ID: 18088466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes.
    del Conde I; Nabi F; Tonda R; Thiagarajan P; López JA; Kleiman NS
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1065-70. PubMed ID: 15705928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
    Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
    Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability.
    Reddy KV; Bhattacharjee G; Schabbauer G; Hollis A; Kempf K; Tencati M; O'Connell M; Guha M; Mackman N
    J Leukoc Biol; 2004 Jul; 76(1):145-51. PubMed ID: 15075360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
    Cavo M; Zamagni E; Tosi P; Tacchetti P; Cellini C; Cangini D; de Vivo A; Testoni N; Nicci C; Terragna C; Grafone T; Perrone G; Ceccolini M; Tura S; Baccarani M;
    Blood; 2005 Jul; 106(1):35-9. PubMed ID: 15761019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.